Update shared on 10 Nov 2025
Fair value Increased 1.39%Analysts have raised their price target for Lupin from ₹2,224.81 to ₹2,255.81. This reflects updated expectations around growth and margin assumptions.
What's in the News
- Lupin Digital Health launched VITALYFE, an AI-powered cardiometabolic wellness platform targeting India's working professionals and addressing corporate health challenges (Key Developments).
- Lupin inaugurated new corporate offices in Bridgewater, New Jersey, to expand its U.S. operations and corporate presence (Key Developments).
- The company announced a new $250 million pharmaceutical manufacturing plant in Coral Springs, Florida. The facility will focus on producing critical respiratory medicines and is expected to create over 200 skilled jobs by 2030 (Key Developments).
- Lupin reported multiple new product launches and FDA approvals in the United States, including bioequivalent versions of established drugs for diabetes, heart health, and pulmonary conditions (Key Developments).
- Lupin partnered with Sandoz Group AG to market and commercialize its biosimilar ranibizumab across Europe, Canada, and selected global markets (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has increased slightly from ₹2,224.81 to ₹2,255.81.
- Discount Rate rose marginally from 12.73% to 12.76%.
- Revenue Growth projections declined from 7.59% to 6.17%.
- Net Profit Margin estimate decreased modestly from 14.75% to 14.36%.
- Future P/E ratio (Price-to-Earnings) edged higher from 34.00x to 34.82x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.